Precigen Inc - Asset Resilience Ratio
Precigen Inc (PGEN) has an Asset Resilience Ratio of 43.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore Precigen Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Precigen Inc's Asset Resilience Ratio has changed over time. See defensive interval ratio of Precigen Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Precigen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PGEN current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.62 Million | 43.18% |
| Total Liquid Assets | $67.62 Million | 43.18% |
Asset Resilience Insights
- Very High Liquidity: Precigen Inc maintains exceptional liquid asset reserves at 43.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Precigen Inc Industry Peers by Asset Resilience Ratio
Compare Precigen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020 |
Biotechnology | 63.76% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
ABCELLERA BIOLOGICS
F:8QQ |
Biotechnology | 29.87% |
Annual Asset Resilience Ratio for Precigen Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Precigen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | $67.62 Million | $156.62 Million | -3.90pp |
| 2024-12-31 | 47.08% | $68.39 Million | $145.27 Million | +10.48pp |
| 2023-12-31 | 36.60% | $55.28 Million | $151.04 Million | +12.94pp |
| 2022-12-31 | 23.66% | $51.09 Million | $215.98 Million | +3.58pp |
| 2021-12-31 | 20.07% | $72.24 Million | $359.86 Million | +4.71pp |
| 2020-12-31 | 15.36% | $48.33 Million | $314.59 Million | +13.33pp |
| 2019-12-31 | 2.03% | $9.26 Million | $455.76 Million | -14.73pp |
| 2018-12-31 | 16.77% | $120.07 Million | $716.18 Million | +15.40pp |
| 2017-12-31 | 1.36% | $11.56 Million | $846.85 Million | -17.03pp |
| 2016-12-31 | 18.40% | $174.60 Million | $949.07 Million | +7.96pp |
| 2015-12-31 | 10.44% | $102.53 Million | $982.05 Million | -4.92pp |
| 2014-12-31 | 15.36% | $88.50 Million | $576.27 Million | -11.90pp |
| 2013-12-31 | 27.26% | $127.98 Million | $469.47 Million | +27.09pp |
| 2012-12-31 | 0.17% | $260.00K | $151.65 Million | -0.05pp |
| 2011-12-31 | 0.22% | $258.00K | $114.83 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more